TY - JOUR
T1 - Integrated management of atrial fibrillation in primary care
T2 - results of the ALL-IN cluster randomized trial
AU - van den Dries, Carline J
AU - van Doorn, Sander
AU - Rutten, Frans H
AU - Oudega, Ruud
AU - van de Leur, Sjef J C M
AU - Elvan, Arif
AU - Oude Grave, Lisa
AU - Bilo, Henk J G
AU - Moons, Karel G M
AU - Hoes, Arno W
AU - Geersing, Geert-Jan
N1 - Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2020/8/7
Y1 - 2020/8/7
N2 - Aims To evaluate whether integrated care for atrial fibrillation (AF) can be safely orchestrated in primary care. Methods The ALL-IN trial was a cluster randomized, open-label, pragmatic non-inferiority trial performed in primary care and results practices in the Netherlands. We randomized 26 practices: 15 to the integrated care intervention and 11 to usual care. The integrated care intervention consisted of (i) quarterly AF check-ups by trained nurses in primary care, also focusing on possibly interfering comorbidities, (ii) monitoring of anticoagulation therapy in primary care, and finally (iii) easy-access availability of consultations from cardiologists and anticoagulation clinics. The primary endpoint was all-cause mortality during 2 years of follow-up. In the intervention arm, 527 out of 941 eligible AF patients aged >_65 years provided informed consent to undergo the intervention. These 527 patients were compared with 713 AF patients in the control arm receiving usual care. Median age was 77 (interquartile range 72-83) years. The all-cause mortality rate was 3.5 per 100 patient-years in the intervention arm vs. 6.7 per 100 patient-years in the control arm [adjusted hazard ratio (HR) 0.55; 95% confidence interval (CI) 0.37-0.82]. For non-cardiovascular mortality, the adjusted HR was 0.47 (95% CI 0.27-0.82). For other adverse events, no statistically significant differences were observed. Conclusion In this cluster randomized trial, integrated care for elderly AF patients in primary care showed a 45% reduction in all-cause mortality when compared with usual care.
AB - Aims To evaluate whether integrated care for atrial fibrillation (AF) can be safely orchestrated in primary care. Methods The ALL-IN trial was a cluster randomized, open-label, pragmatic non-inferiority trial performed in primary care and results practices in the Netherlands. We randomized 26 practices: 15 to the integrated care intervention and 11 to usual care. The integrated care intervention consisted of (i) quarterly AF check-ups by trained nurses in primary care, also focusing on possibly interfering comorbidities, (ii) monitoring of anticoagulation therapy in primary care, and finally (iii) easy-access availability of consultations from cardiologists and anticoagulation clinics. The primary endpoint was all-cause mortality during 2 years of follow-up. In the intervention arm, 527 out of 941 eligible AF patients aged >_65 years provided informed consent to undergo the intervention. These 527 patients were compared with 713 AF patients in the control arm receiving usual care. Median age was 77 (interquartile range 72-83) years. The all-cause mortality rate was 3.5 per 100 patient-years in the intervention arm vs. 6.7 per 100 patient-years in the control arm [adjusted hazard ratio (HR) 0.55; 95% confidence interval (CI) 0.37-0.82]. For non-cardiovascular mortality, the adjusted HR was 0.47 (95% CI 0.27-0.82). For other adverse events, no statistically significant differences were observed. Conclusion In this cluster randomized trial, integrated care for elderly AF patients in primary care showed a 45% reduction in all-cause mortality when compared with usual care.
KW - Anticoagulation
KW - Atrial fibrillation
KW - Integrated care
KW - Multimorbidity
KW - Primary care
U2 - 10.1093/eurheartj/ehaa055
DO - 10.1093/eurheartj/ehaa055
M3 - Article
C2 - 32112556
SN - 0195-668X
VL - 41
SP - 2836
EP - 2844
JO - European heart journal
JF - European heart journal
IS - 28
ER -